Next Article in Journal
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
Next Article in Special Issue
Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells
Previous Article in Journal
Tumor Metabolism of Malignant Gliomas
Previous Article in Special Issue
Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR
Cancers 2013, 5(4), 1485-1503; doi:10.3390/cancers5041485
Article

Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer

1,2
, 1
, 3
, 3,4
, 5
, 6
 and 1,*
Received: 29 August 2013; in revised form: 7 October 2013 / Accepted: 1 November 2013 / Published: 8 November 2013
(This article belongs to the Special Issue Circulating Tumor Cells in Cancers)
View Full-Text   |   Download PDF [345 KB, uploaded 8 November 2013]   |   Browse Figures
Abstract: Breast cancers can metastasize via hematogenous and lymphatic routes, however in some patients only one type of metastases are detected, suggesting a certain proclivity in metastatic patterns. Since epithelial-mesenchymal transition (EMT) plays an important role in cancer dissemination it would be worthwhile to find if a specific profile of EMT gene expression exists that is related to either lymphatic or hematogenous dissemination. Our study aimed at evaluating gene expression profile of EMT-related markers in primary tumors (PT) and correlated them with the pattern of metastatic spread. From 99 early breast cancer patients peripheral blood samples (N = 99), matched PT (N = 47) and lymph node metastases (LNM; N = 22) were collected. Expression of TWIST1, SNAI1, SNAI2 and VIM was analyzed in those samples. Additionally expression of CK19, MGB1 and HER2 was measured in CTCs-enriched blood fractions (CTCs-EBF). Results were correlated with each other and with clinico-pathological data of the patients. Results show that the mesenchymal phenotype of CTCs-EBF correlated with poor clinico-pathological characteristics of the patients. Additionally, PT shared more similarities with LNM than with CTCs-EBF. Nevertheless, LNM showed increased expression of EMT-related markers than PT; and EMT itself in PT did not seem to be necessary for lymphatic dissemination.
Keywords: breast cancer; lymph node metastasis; circulating tumor cells; metastasis; cancer dissemination; epithelial-mesenchymal transition breast cancer; lymph node metastasis; circulating tumor cells; metastasis; cancer dissemination; epithelial-mesenchymal transition
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Markiewicz, A.; Książkiewicz, M.; Seroczyńska, B.; Skokowski, J.; Szade, J.; Wełnicka-Jaśkiewicz, M.; Zaczek, A.J. Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. Cancers 2013, 5, 1485-1503.

AMA Style

Markiewicz A, Książkiewicz M, Seroczyńska B, Skokowski J, Szade J, Wełnicka-Jaśkiewicz M, Zaczek AJ. Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. Cancers. 2013; 5(4):1485-1503.

Chicago/Turabian Style

Markiewicz, Aleksandra; Książkiewicz, Magdalena; Seroczyńska, Barbara; Skokowski, Jarosław; Szade, Jolanta; Wełnicka-Jaśkiewicz, Marzena; Zaczek, Anna J. 2013. "Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer." Cancers 5, no. 4: 1485-1503.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert